TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAEs) in participants with multiple sclerosis (MS) treated with TYSABRI (natalizumab).
Epistemonikos ID: 34833982efd117f65075be03428bbd5725e52714
First added on: May 04, 2024